Updates are available Correction dated 2020-08-21
Click to view Correction: https://doi.org/10.1038/s41398-020-00983-3
-
Authors
Yang, C
Shirayama, Y
Zhang, J-c
Ren, Q https://orcid.org/0000-0003-2982-8824
Yao, W
Ma, M
Dong, C
Hashimoto, K
- License Information
-
More Information
Article History
Received: 28 July 2015
Revised: 30 July 2015
Accepted: 30 July 2015
First Online: 1 September 2015
Change Date: 21 August 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-020-00983-3
Competing interests
: Dr Hashimoto is an inventor on a filed patent application on 'The use of <i>R</i>-ketamine in the treatment of psychiatric diseases' by Chiba University. Dr Hashimoto has served as a scientific consultant to Astellas and Taisho, and he has also received research support from Abbvie, Dainippon Sumitomo, Mochida, Otsuka and Taisho. Dr Shirayama has received research support from Eli Lilly, Eisai, MSD, Otsuka, Pfizer, Taisho, Takeda and Mitsubishi-Tanabe. The remaining authors declare no conflict of interest.
